4/4/2013

The FDA approved Tris Pharma's Karbinal ER, or carbinoxamine maleate, for pediatric patients 2 years and older, to treat seasonal and perennial allergic rhinitis. The treatment is the first extended-release histamine receptor blocking agent for children's allergies, Tris said.

Full Story:
Drug Store News

Related Summaries